Nuvectis Pharma Statistics
Share Statistics
Nuvectis Pharma has 19.32M shares outstanding. The number of shares has increased by 7.65% in one year.
| Shares Outstanding | 19.32M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.62% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 8.93M |
| Failed to Deliver (FTD) Shares | 2.55K |
| FTD / Avg. Volume | 1.47% |
Short Selling Information
The latest short interest is 1.13M, so 5.85% of the outstanding shares have been sold short.
| Short Interest | 1.13M |
| Short % of Shares Out | 5.85% |
| Short % of Float | 13.21% |
| Short Ratio (days to cover) | 7.94 |
Valuation Ratios
The PE ratio is -5.83 and the forward PE ratio is -11.44.
| PE Ratio | -5.83 |
| Forward PE | -11.44 |
| PS Ratio | 0 |
| Forward PS | 4 |
| PB Ratio | 10.63 |
| P/FCF Ratio | -8.13 |
| PEG Ratio | n/a |
Enterprise Valuation
Nuvectis Pharma Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.75, with a Debt / Equity ratio of 0.
| Current Ratio | 2.75 |
| Quick Ratio | 2.75 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.82% and return on capital (ROIC) is -187.66%.
| Return on Equity (ROE) | -1.82% |
| Return on Assets (ROA) | -1.16% |
| Return on Capital (ROIC) | -187.66% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.71M |
| Employee Count | 13 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -45.06% in the last 52 weeks. The beta is 0.4, so Nuvectis Pharma 's price volatility has been higher than the market average.
| Beta | 0.4 |
| 52-Week Price Change | -45.06% |
| 50-Day Moving Average | 6.56 |
| 200-Day Moving Average | 6.94 |
| Relative Strength Index (RSI) | 37.53 |
| Average Volume (20 Days) | 174.01K |
Income Statement
In the last 12 months, Nuvectis Pharma had revenue of $0 and earned -$22.26M in profits. Earnings per share was $-1.43.
| Revenue | 0 |
| Gross Profit | -22.90M |
| Operating Income | -22.90M |
| Net Income | -22.26M |
| EBITDA | -22.90M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.43 |
Balance Sheet
The company has $19.13M in cash and $0 in debt, giving a net cash position of $19.13M.
| Cash & Cash Equivalents | 19.13M |
| Total Debt | 0 |
| Net Cash | 19.13M |
| Retained Earnings | -54.24M |
| Total Assets | 17.31M |
| Working Capital | 10.99M |
Cash Flow
In the last 12 months, operating cash flow was -$15.95M and capital expenditures $0, giving a free cash flow of -$15.95M.
| Operating Cash Flow | -15.95M |
| Capital Expenditures | 0 |
| Free Cash Flow | -15.95M |
| FCF Per Share | -1.03 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
NVCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -30.23% |
| FCF Yield | -17.45% |
Analyst Forecast
The average price target for NVCT is $21, which is 344% higher than the current price. The consensus rating is "Buy".
| Price Target | $21 |
| Price Target Difference | 344% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -0.15 |
| Piotroski F-Score | 1 |